3/26
09:23 am
rnxt
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment [Yahoo! Finance]
Low
Report
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment [Yahoo! Finance]
3/26
08:30 am
rnxt
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
Medium
Report
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
3/23
09:14 am
rnxt
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement [Yahoo! Finance]
Medium
Report
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement [Yahoo! Finance]
3/23
08:30 am
rnxt
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Medium
Report
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
3/20
09:03 am
rnxt
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET [Yahoo! Finance]
Low
Report
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET [Yahoo! Finance]
3/18
09:18 am
rnxt
RenovoRx Announces $10 Million at Market Private Placement [Yahoo! Finance]
Neutral
Report
RenovoRx Announces $10 Million at Market Private Placement [Yahoo! Finance]
3/18
09:12 am
rnxt
RenovoRx announces $10 million private placement [Seeking Alpha]
Low
Report
RenovoRx announces $10 million private placement [Seeking Alpha]
3/18
08:35 am
rnxt
RenovoRx Announces $10 Million at Market Private Placement
Medium
Report
RenovoRx Announces $10 Million at Market Private Placement
3/15
01:05 am
rnxt
High
Report
3/7
02:59 am
rnxt
Low
Report
2/28
09:08 am
rnxt
RenovoRx advances RenovoCath adoption at U.S. cancer centers [Yahoo! Finance]
Low
Report
RenovoRx advances RenovoCath adoption at U.S. cancer centers [Yahoo! Finance]
2/27
08:50 am
rnxt
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum [Yahoo! Finance]
Medium
Report
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum [Yahoo! Finance]
2/27
08:30 am
rnxt
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
Medium
Report
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
2/26
08:54 am
rnxt
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting [Yahoo! Finance]
Medium
Report
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting [Yahoo! Finance]
2/26
08:30 am
rnxt
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
Medium
Report
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
2/17
08:03 am
rnxt
RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.50 to $13.00. They now have a "buy" rating on the stock.
Low
Report
RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.50 to $13.00. They now have a "buy" rating on the stock.
2/14
01:32 am
rnxt
Medium
Report
2/10
08:30 am
rnxt
RenovoRx Establishes RenovoCath® Medical Advisory Board
Medium
Report
RenovoRx Establishes RenovoCath® Medical Advisory Board
2/5
08:30 am
rnxt
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Low
Report
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
2/4
08:30 am
rnxt
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Medium
Report
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
1/31
07:46 am
rnxt
RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
Medium
Report
RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
1/28
08:30 am
rnxt
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
Low
Report
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
1/20
08:30 am
rnxt
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
Medium
Report
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
1/18
08:21 am
rnxt
Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Medium
Report
Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
1/14
08:30 am
rnxt
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
Low
Report
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026